Navigation Links
ABAXIS Announces Launch of Two New Products at the NAVC
Date:1/16/2009

ng statements contained in this press release include, but are not limited to, risks and uncertainties related to the market acceptance of the Company's products and the continuing development of its products, risks associated with manufacturing and distributing its products on a commercial scale, risks associated with entering the human diagnostic market on a larger scale, risks involved in carrying of inventory, risks from unexpected problems or delays in the Company's manufacturing facility, risks associated with the ability to attract and retain competent sales personnel, general market conditions, competition, risks and uncertainties related to its ability to raise capital in order to fund its operations and other risks detailed from time to time in Abaxis' periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statement was made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements. 

    Clint Severson               Lytham Partners, LLC
    Chief Executive Officer      Joe Dorame, Robert Blum and Joe Diaz
    Abaxis, Inc.                 602-889-9700
    510-675-6500


'/>"/>
SOURCE Abaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd.
2. Abaxis, Inc. to Present at Sidoti & Companys Sixth Annual Palm Beach Emerging Growth Institutional Investor Forum
3. Abaxis, Inc. to Present at Needham & Companys Eleventh Annual Growth Stock Conference
4. Abaxis Point-of-Care Test Panels Gain FDA CLIA-Waived Status
5. Abaxis, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
6. Abaxis to Report Second Quarter Fiscal 2009 Financial Results Monday, October 27, 2008
7. Abaxis, Inc. to Present at CL Kings Sixth Annual Best Ideas Conference
8. Abaxis, Inc. CEO to Present at the Eighth Annual Forbes Global CEO Conference in Singapore
9. Abaxis to Report First Quarter Fiscal 2009 Financial Results Thursday, July 24, 2008
10. Abaxis to Present at the SunTrust Robinson Humphreys 37th Annual Institutional Unconference
11. Abaxis, Inc. to Present at the Sidoti & Company Twelfth Annual New York Emerging Growth Institutional Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 2Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 3Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8